## AMENDMENTS TO THE CLAIMS

1. (Original) A formulation for treating cancer, comprising:
a component of blood obtained from a patient to be treated; and
a pharmaceutically acceptable carrier.

2. (Original) The formulation of claim 1, wherein the component of blood is platelet-rich-plasma (PRP).

3. (Original) The formulation of claim 2, wherein the PRP is subjected to energy wves to form a platelet releasate.

4. (Original) The formulation of claim 3, wherein a protein component of the platelet releasate is removed.

5. (Original) The formulation of claim 3, wherein a plurality of components of the platelet releasate are removed.

6. (Original) The formulation of claim 3, further comprising:
a recombinantly produced human protein.

7. (Original) The formulation of claim 1, wherein the carrier is an injectable carrier.

8. (Original) The formulation of claim 7, wherein the injectable carrier comprises a pH buffering agent.

9. (Original) The formulation of claim 3, wherein substantially all human growth hormone naturally present in the platelet releasate is removed.

10. (Original) The formulation of claim 3, further comprising:

biocarbonate buffer in a molarity sufficient to adjust formulation pH to within a range of about 7.2 to about 7.6.

11. (Original) A method comprising:

extracting blood from a patient;

concentrating platelets from the blood;

processing the platelets in a manner which breaks open the platelets and obtaining a platelet releasate; and

administering the platelet releasate to the patient.

12. (Original) The method of claim 11, wherein the processing comprises exposing the platelets to energy waves.

13. (Original) The method of claim 11, wherein the administering comprises injecting the platelet releasate into a tumor of the patient.

14. (Original) The method of claim 1, wherein the administering comprises injecting the platelet releasate into a cancerous tumor of the patient.

15. (Original) The method of claim 14, further comprising:

separating a substantially all growth factor protein from the platelet releasate prior to administering the platelet releasate to the patient.

16. (Original) A method of treating cancer, comprising:

extracting blood from a patient;

concentrating platelets from the blood;

processing the platelets in a manner which breaks open the platelets obtaining a platelet releasate;

formulating the platelet releasate into an injectable formulation buffered to a pH of 7.4 ± 5%; and

administering a therapeutically effective amount of the formulation to a patient.

17. (Original) The method of claim 9 wherein the patient treated with the formulation is the same patient from which the blood is extracted from, and the formulation is buffered to pH 7.4 ± 2%; and wherein the platelets are processed for a period of time and under conditions so as to break open 90% or more of the platelets; and further wherein the patient from which the blood is extracted is the same patient to which the formulation is administered.

18. (Original) The method of claim 17, further comprising:

repeatedly administering a therapeutically effective amount of the formulation to the patient over a period of time while monitoring the patient and adjusting dosing to effectively treat the cancer.

19. (Original) A method of treatment, comprising:

extracting blood from a patient;

concentrating platelets from the blood;

processing the platelets in a manner which breaks open the platelets obtaining a platelet releasate;

placing cells on a culture median comprising the platelet releasate;

allowing the cells to proliferate on the culture medium;

isolating the cultured cells;

formulating the isolated cells into an injectable formulations; and

administering the injectable formulation to a patient.

20. (Original) The method of claim 19, wherein the cells placed on the culture medium are obtained from the same patient the blood is extracted and the cells are from the patient's bone marrow prior to subjecting the patient to radiation;

wherein the ultrasound processing is carried out for a period of time and under conditions so as to break open 90% or more of the platelets; and

wherein the blood is extracted from the same patient as the cells and the cells comprise adult stem cells.

21-28. (Cancelled)